Vanda Pharmaceuticals
VNDA
179 hedge funds and large institutions have $967M invested in Vanda Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 81 increasing their positions, 44 reducing their positions, and 39 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 44
2.21% more ownership
Funds ownership: 101.09% → 103.3% (+2.2%)
4% less funds holding
Funds holding: 186 → 179 (-7)
18% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 39
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $1.35B → $967M (-$378M)
32% less call options, than puts
Call options by funds: $1.44M | Put options by funds: $2.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$27.4M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$23.7M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$20.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$12.9M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.6M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$17.5M |
| 3 |
First Manhattan
New York
|
-$12.8M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$9.12M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$7.44M |
VNDA Hedge Fund Activity: Q1 2019 in Review
179 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2019, worth a combined $967M — down 28% from $1.35B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of VNDA and 32 opened new positions — a net loss of 7 holders — while 44 trimmed existing stakes and 81 added.
The largest buyer was State Street, adding an estimated $27.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $36.6M sold.
- 179 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2019, down from 186 in Q4 2018.
- Funds reported $967M of Vanda Pharmaceuticals stock for Q1 2019, down 28% quarter-over-quarter.
- 32 funds opened new Vanda Pharmaceuticals positions in Q1 2019 and 39 closed out, a net change of -7 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2019 was State Street, an estimated $27.4M added.
- The largest Vanda Pharmaceuticals seller in Q1 2019 was Adage Capital Partners, an estimated $36.6M sold.
Based on aggregated 13F filings for Q1 2019.